M
Michael J. Rinaldi
Researcher at Carolinas Healthcare System
Publications - 48
Citations - 5825
Michael J. Rinaldi is an academic researcher from Carolinas Healthcare System. The author has contributed to research in topics: Percutaneous coronary intervention & Clopidogrel. The author has an hindex of 18, co-authored 36 publications receiving 4882 citations. Previous affiliations of Michael J. Rinaldi include Columbia University Medical Center & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Laura Mauri,Dean J. Kereiakes,Robert W. Yeh,Priscilla Driscoll-Shempp,Donald E. Cutlip,P. Gabriel Steg,P. Gabriel Steg,Sharon-Lise T. Normand,Eugene Braunwald,Stephen D. Wiviott,David J. Cohen,David R. Holmes,Mitchell W. Krucoff,James B. Hermiller,Harold L. Dauerman,Daniel I. Simon,David E. Kandzari,Kirk N. Garratt,David P. Lee,Thomas K. Pow,Peter Ver Lee,Michael J. Rinaldi,Joseph M. Massaro,Joseph M. Massaro +23 more
TL;DR: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
Journal ArticleDOI
Percutaneous Repair or Surgery for Mitral Regurgitation
Ted Feldman,Elyse Foster,Donald D. Glower,Saibal Kar,Michael J. Rinaldi,Peter S. Fail,Richard W. Smalling,Robert J. Siegel,Geoffrey A. Rose,Eric Engeron,Catalin Loghin,Alfredo Trento,Eric R. Skipper,Tommy Fudge,George V. Letsou,Joseph M. Massaro,Laura Mauri +16 more
TL;DR: Although percutaneous repair was less effective at reducing mitral regurgitation than conventional surgery, the procedure was associated with superior safety and similar improvements in clinical outcomes.
Journal ArticleDOI
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Robert W. Yeh,Robert W. Yeh,Eric A. Secemsky,Dean J. Kereiakes,Sharon-Lise T. Normand,Anthony H. Gershlick,Anthony H. Gershlick,David J. Cohen,John A. Spertus,John A. Spertus,Philippe Gabriel Steg,Philippe Gabriel Steg,Donald E. Cutlip,Donald E. Cutlip,Michael J. Rinaldi,Edoardo Camenzind,William Wijns,Patricia Apruzzese,Yang Song,Joseph M. Massaro,Joseph M. Massaro,Laura Mauri,Laura Mauri +22 more
TL;DR: A clinical decision tool to identify patients expected to derive benefit vs harm from continuing thienopyridine beyond 1 year after percutaneous coronary intervention is developed to inform dual antiplatelet therapy duration.
Journal ArticleDOI
Percutaneous Repair or Surgery for Mitral Regurgitation
Ted Feldman,Elyse Foster,Donald D. Glower,Saibal Kar,Michael J. Rinaldi,Peter S. Fail,Richard W. Smalling,Robert J. Siegel,Geoffrey A. Rose,Eric Engeron,Catalin Loghin,Alfredo Trento,Eric R. Skipper,Tommy Fudge,George V. Letsou,Joseph M. Massaro,Laura Mauri +16 more
TL;DR: Ted Feldman, M.D., Elyse Foster, M,D.
Journal ArticleDOI
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Study
Bernhard Witzenbichler,Akiko Maehara,Giora Weisz,Franz-Josef Neumann,Michael J. Rinaldi,D. Christopher Metzger,Timothy D. Henry,David A. Cox,Peter L. Duffy,Bruce R. Brodie,Thomas Stuckey,Ernest L. Mazzaferri,Ke Xu,Helen Parise,Roxana Mehran,Gary S. Mintz,Gregg W. Stone +16 more
TL;DR: In ADAPT-DES, the largest study of IVUS use to date, IVUS guidance was associated with a reduction in stent thrombosis, myocardial infarction, and major adverse cardiac events within 1 year after DES implantation.